Corona Remedies Regulatory Approval

Legal & Regulatory

Corona Remedies Legal & Regulatory

Corona Remedies received an NPPA demand notice of Rs 4.88 Crore for alleged DPCO 2013 price violations. The company is evaluating it and reports no material financial impact.

Value

₹4.88 Cr

Earnings Call

Corona Remedies Earnings Call Transcript: Key Takeaways

CORONA delivered robust revenue growth of 22% YoY, outperforming the Indian pharmaceutical market by focusing on chronic segments. Management maintains a growth target of 1.5x the market rate.

Call

Guides 15% growth

Earnings Call

Corona Remedies Investor Presentation: Key Takeaways

Q2FY27 revenue ₹441.2Cr (+22.2%), PAT ₹60.3Cr (+15.3%); H1 revenue ₹863.6Cr (+22.0%), PAT ₹120.4Cr (+22.2%). Chronic-led growth, outpacing IPM.

Results Update

Corona Remedies Results Update

Corona Remedies released unaudited Q2 and H1 FY27 results highlights via press release. Revenue grew 22% year on year, with EBITDA and PAT also rising.

Financial Results

Corona Remedies Q2 FY27 Results: Net Profit ₹60.3 Cr, Up 15.3% YoY

Corona Remedies Ltd reported revenue from operations of ₹441.2 Cr (+22.2% YoY) and net profit of ₹60.3 Cr (+15.3% YoY) for Q2 FY27.

Key figure

Net profit ₹60.3 Cr · +15.3% YoY

Business Update

Corona Remedies Business Update

Corona Remedies received GMP Compliance Certification from Brazil's ANVISA for its OSD and Hormone facilities in Ahmedabad. This validates export eligibility to the Brazilian pharmaceutical market.

Regulatory ApprovalWanbury Ltd WANBURYAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Wanbury Regulatory Approval

Wanbury received ANVISA (Brazil FDA) CADIFA approval for Metformin HCl EP grade API, its third consecutive ANVISA clearance. The company has initiated customer talks to increase API volumes in Brazil.

Regulatory ApprovalSandur Manganese & Iron Ores Ltd SANDUMAAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Sandur Manganese & Iron Ores Regulatory Approval

Sandur Manganese received environmental clearance to raise iron ore capacity to 9.42 MTPA. No rupee value is disclosed in the filing.

iron ore RoM capacity

9.42 MTPA

Regulatory ApprovalNeogen Chemicals Ltd NEOGENAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Neogen Chemicals Regulatory Approval

Neogen Chemicals received GPCB's revocation of its Dahej plant direction and a CC&A amendment for manufacturing. The revocation is for three months with conditions attached.

Regulatory ApprovalArihant Capital Markets Ltd ARIHANTCAPAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Arihant Capital Markets Regulatory Approval

Arihant Capital Markets received SEBI in-principle approval to sponsor and set up a mutual fund. Final registration remains subject to SEBI's conditions.

Regulatory ApprovalDr. Reddy's Laboratories Ltd DRREDDYAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Dr. Reddy's Laboratories Regulatory Approval

Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.

Regulatory ApprovalAlembic Pharmaceuticals Ltd APLLTDAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.